Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis BB-12 (Chr. Hansen)
- Development stage
- Unknown
- Lead developer
- Georgetown University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Bifidobacterium animalis subsp. lactis BB-12** is a defined, orally administered probiotic bacterial strain commercialized as **BB-12**. Originally developed by Chr. Hansen and now supplied within Novonesis, it is used in dietary supplements, infant formula, and fermented dairy products. BB-12 survives gastrointestinal transit and is thought to act through strain-dependent interactions with the intestinal ecosystem, including epithelial adherence, support of intestinal barrier function, modulation of gut microbial communities, pathogen exclusion, and immune modulation rather than through a single druggable molecular target. Clinical studies have evaluated it for low defecation frequency, infant colic, and prevention of illness-related daycare absences associated with diarrhea and upper respiratory tract infections. ([novonesis.com](https://www.novonesis.com/en/biosolutions/human-health/b-lactis-bb-12))
- Brand names
- BB-12BB12BB 12
- Other names
- B. lactis BB-12Bifidobacterium animalis subsp. lactis BB-12Bifidobacterium lactis BB-12
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis BB-12 (Chr. Hansen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis BB-12 (Chr. Hansen).